Ancient herbs take on long COVID: a trial tests whether chinese medicine can soothe persistent fatigue
NCT ID NCT04924881
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a Chinese herbal formula, COVID Rehab Formula, can reduce fatigue and other lingering symptoms in people who have recovered from COVID-19. Participants take the herbal granules or a placebo daily for 8 weeks. The study focuses on those with ongoing fatigue plus at least one other symptom, such as breathlessness, cough, or sleep problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a Chinese herbal formula called COVID Rehab Formula granules
- What this could lead to
- If it works, this could offer a treatment option for persistent fatigue and other lingering symptoms after COVID-19.
- What could go wrong
- This is a small, early-phase trial with only 68 participants, so results may not apply widely. Herbal formulas can also have side effects or interact with other medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Chinese University of Hong Kong
Shatin, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a different way of pedaling rebuild muscles after severe COVID-19?
- Can a 15-Minute chat at a testing site boost COVID-19 vaccination?
- E-Ink screens in ERs could boost patient satisfaction
- Massive study tracks how lockdowns shaped mental health across america
- Hidden danger: study probes blood clot risk in cancer patients with COVID-19
- Experimental drug aims to tame severe COVID-19 inflammation